Trial Profile

Phase II multicentre ,randomized clinical trial of of ILB® in Amyotrophic Lateral Sclerosis .

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dextran sulfate (Primary) ; Riluzole
Indications Amyotrophic lateral sclerosis
Focus Therapeutic Use

Most Recent Events

23 Oct 2025 New trial record
01 Sep 2025 According to Tikomed media release,The study is sponsored by Oslo University Hospital, funded by public research grants and is open to Norwegian residents only. Tikomed will supply ILB for both study phases as well as corresponding placebo for the RCT.
01 Sep 2025 According to Tikomed media release, this study has received all required regulatory approvals and is expected to start enrolling patients during the first quarter of 2026. Results are expected by the end of 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com